CHEMO-FREE FIRST-LINE THERAPY IN FRAIL PATIENTS WITH MARGINAL AND MANTLE CELL NON-HODGKIN LYMPHOMA: OUR EXPERIENCE (EHA 2026) - May 12, 2026 - Abstract #EHA-5300; PB3671; "Aims The aim of our study is to treat frail patients diagnosed with mNHL or MNHL with a single dose of bendamustine 70 mg/m2 immediately discontinued, followed by one weekly cycle of rituximab 375 mg/m2, after which iBKT (zanubrutinib for MNHL and acalabrutinib for mNHL) was added concurrently with immunotherapy (Rituxmab 375 mg/m2, one dose every 28 days for 4 administrations)...No patients experienced grade >2 cardiac adverse events; 3/22 patients (14%) experienced grade >2 bleeding events that led to iBKT discontinuation with subsequent resumption at a 50% reduced dose; no patients experienced >2 hematological toxicity; no patients experienced CMV reactivation (from retrospective data from our center, approximately 25% of patients treated with R-Benda had developed CMV reactivation); 2 patients (9%) developed serious fungal infection (maxillary sinus mucormycosis with death and pulmonary aspergilloma treated with isavuconazole)...(figure 1)..."
Clinical • Breast Cancer • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin's Lymphoma • Solid Tumor
|
|
Luca Pezzullo 1; Antonella Malandrini 1,2; Andrea Gigantiello 1,2; Lorenzo Settembre 1,2; Giovanni Signorile 1,2; Valentina Giudice 2; Carmine Selleri 1,2
|